According to trading documents cited by Bloomberg, Pharmaron, a shareholder of WUXI XDC (02268.HK), is seeking to raise up to HK$2.4 billion through block trading. According to the terms of the sales documents, Pharmaron plans to sell 30.3 million shares of WUXI XDC at a price range of HK$77 to HK$79.07 per share, representing a discount of 4.5% to 7% compared to WUXI XDC's closing price of HK$82.8 on Wednesday (October 8).

The shares for sale represent approximately 2.47% of WUXI XDC's existing outstanding shares, with a 90-day lock-up period for the seller. Morgan Stanley serves as the sole bookrunner for this transaction.

According to equity disclosure on the Hong Kong Stock Exchange website, Pharmaron directly holds 263.2 million shares, or 21.89% of WUXI XDC. WUXI APPTEC (02359.HK) indirectly holds a 98.9% interest in Pharmaron. In addition to WUXI APPTEC, WuXi Biologics (02269.HK) also holds 635.4845 million shares, or 51.76% of WUXI XDC's equity.